- United States
- /
- Life Sciences
- /
- NYSE:DNA
Ginkgo Bioworks Holdings Director Marijn Dekkers Sells 86% Of Holding
We wouldn't blame Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) shareholders if they were a little worried about the fact that Marijn Dekkers, the Director recently netted about US$1.6m selling shares at an average price of US$0.93. That diminished their holding by a very significant 86%, which arguably implies a strong desire to reallocate capital.
See our latest analysis for Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings Insider Transactions Over The Last Year
Notably, that recent sale by Marijn Dekkers is the biggest insider sale of Ginkgo Bioworks Holdings shares that we've seen in the last year. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$0.77. So it is hard to draw any strong conclusion from it.
In the last twelve months insiders purchased 922.62k shares for US$787k. But insiders sold 1.77m shares worth US$1.7m. In total, Ginkgo Bioworks Holdings insiders sold more than they bought over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.
Insider Ownership Of Ginkgo Bioworks Holdings
Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Ginkgo Bioworks Holdings insiders own about US$302m worth of shares (which is 17% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
So What Does This Data Suggest About Ginkgo Bioworks Holdings Insiders?
The insider sales have outweighed the insider buying, at Ginkgo Bioworks Holdings, in the last three months. Zooming out, the longer term picture doesn't give us much comfort. It is good to see high insider ownership, but the insider selling leaves us cautious. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. At Simply Wall St, we found 4 warning signs for Ginkgo Bioworks Holdings that deserve your attention before buying any shares.
But note: Ginkgo Bioworks Holdings may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NYSE:DNA
Ginkgo Bioworks Holdings
Develops a platform for cell programming in the United States.
Flawless balance sheet and slightly overvalued.
Similar Companies
Market Insights
Community Narratives

